Furthermore, the BET inhibitor NHWD-870 acts synergistically with the MEK inhibitor trametinib to suppress melanoma growth, suggesting a promising combination-therapy strategy for melanoma treatment. This evidence concerns the gene MAP2K7 and melanoma.